AAVantgarde Bio
PrivateLast Round
Series B
Nov 3, 2025
Total Funding Raised
$210.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
AAVantgarde Bio is a biotechnology company that develops gene therapies for inherited retinal disorders, utilizing proprietary Adeno-Associated Viral (AAV) vector platforms to deliver large genes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AAVantgarde Bio Comparables
Compare AAVantgarde Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SpliceBio | 89% | |
| Atsena Therapeutics | 86% | |
| Opus Genetics | 79% |
AAVantgarde Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 3, 2025 | ||||
| Series A | Jun 6, 2023 | ||||
| Seed | Jun 30, 2021 | ||||
| Seed | Jun 1, 2021 |
Key People
Founding team and executive leadership
AAVantgarde Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series A |
| Sixty Degree Capital | Series B |
| XGEN Venture | Series B |
| Forbion | Series A, Series B |
| Neva SGR | Series B |
| Athos KG | Series B |
| Accomplice | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 12, 2026
Will present at the 44th Annual J.P. Morgan Healthcare Conference.
- Nov 3, 2025
$141M round completed.
Recent news
Latest coverage and updates
- attends_eventSep 16, 2026
AAVantgarde Bio S.r.l. will attend event Ophthalmology Futures Forum on Sep 30th '26.
- attends_eventSep 16, 2026
AAVantgarde Bio S.r.l. will attend event EURetina 2026 on Oct 4th '26.
- attends_eventSep 16, 2026
AAVantgarde Bio S.r.l. will attend event 26th European Society of Retina Specialists (EURETINA) Annual Congress on Oct 4th '26.
- hiresSep 1, 2026
AAVantgarde Bio S.r.l. hired Megan Zoschg Canniere as Chief Regulatory & Quality officer on Sep 1st '26.
AAVantgarde Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about AAVantgarde Bio's valuation, stock price, and market status.
Is AAVantgarde Bio a public or private company?
AAVantgarde Bio is a private company.
What is the current stock price of AAVantgarde Bio?
AAVantgarde Bio is a private company with no public stock price. No recent secondary market data is available.
How much is AAVantgarde Bio worth (valuation)?
Valuation information for AAVantgarde Bio is not publicly available.
Can I buy AAVantgarde Bio stock?
AAVantgarde Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was AAVantgarde Bio's last funding round?
AAVantgarde Bio's most recent funding round was Series B on November 3, 2025.
Who are the main investors in AAVantgarde Bio?
Key investors in AAVantgarde Bio include Forbion Capital Partners, Forbion, Accomplice, Sofinnova Partners, Atlas Venture.
Will AAVantgarde Bio IPO soon?
No public IPO plans have been announced for AAVantgarde Bio.
How can I track AAVantgarde Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AAVantgarde Bio's secondary market activity and sign up for updates.